{
    "clinical_study": {
        "@rank": "43571", 
        "arm_group": [
            {
                "arm_group_label": "Study Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants at 6 months to < 36 months age at enrollment"
            }, 
            {
                "arm_group_label": "Study Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants at 3 years to < 9  age at enrollment"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the safety and immunogenicity of Fluzone\u00ae Quadrivalent\n      vaccine in participants aged 6 months to < 9 years at enrollment, divided into 2 age strata\n      (6 months to < 36 months and 3 years to < 9 years)\n\n      Primary Objective:\n\n        -  To describe the safety of the 2013-2014 formulation of Fluzone Quadrivalent vaccine,\n           administered in a 1- or 2-dose schedule, in accordance with Advisory Committee on\n           Immunization Practices' (ACIP) recommendations, in children 6 months to < 9 years of\n           age.\n\n      Observational Objectives:\n\n        -  To describe the immunogenicity of the 2013-2014 formulation of Fluzone Quadrivalent\n           vaccine, administered in a 1- or 2-dose schedule in accordance with ACIP\n           recommendations, in children 6 months to < 9 years of age.\n\n        -  To submit sera from subjects to the Center for Biologics Evaluation and Research (CBER)\n           for further analysis by the World Health Organization (WHO), the Centers for Disease\n           Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support\n           formulation recommendations for subsequent influenza vaccines."
        }, 
        "brief_title": "Safety and Immunogenicity Among Healthy Children Receiving Fluzone\u00ae Quadrivalent Influenza Virus Vaccine", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "Participants will be assigned to the appropriate age group (6 months to < 36 months of age\n      or 3 years to < 9 years of age) based on the subject's age at the time of enrollment.\n\n      Solicited adverse event (AE) information will be collected for 7 days after each\n      vaccination, unsolicited AE information will be collected from Visit 1 to Visit 2, or to\n      Visit 3 for those subjects receiving 2 doses. Serious adverse event information will be\n      collected from Visit 1 to Visit 2 or Visit 3, as appropriate.\n\n      Immunogenicity will be evaluated in all subjects prior to vaccination on Day 0 (Visit 1) and\n      at Day 28 after the final vaccination using the hemagglutination inhibition technique. For\n      each influenza vaccine strain, pre- and post-vaccination geometric mean titers will be\n      calculated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is 6 months to < 9 years of age on the day of first study vaccination (study\n             product administration)\n\n          -  Subject and parent/legally acceptable representative are willing and able to attend\n             scheduled visits and to comply with the study procedures during the entire duration\n             of the study\n\n          -  Assent form has been signed and dated by subjects 7 to < 9 years of age, and informed\n             consent form has been signed and dated by parent(s) or another legally acceptable\n             representative\n\n          -  For subjects 6 months to < 12 months of age, born at full term of pregnancy (\u2265 37\n             weeks) and with a birth weight \u2265 2.5 kg (5.5 lbs.) Exclusion Criteria:\n\n          -  Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine\n             components, or a history of a life-threatening reaction to Fluzone Quadrivalent\n             vaccine or to a vaccine containing any of the same substances (the complete list of\n             vaccine components is included in the Prescribing Information)\n\n          -  History of serious adverse reaction to any influenza vaccine\n\n          -  Receipt of any vaccine within 30 days before  receiving study vaccine, or plans to\n             receive another vaccine before Visit 2 for subjects receiving 1 dose of influenza\n             vaccine or Visit 3 for subjects receiving 2 doses of influenza vaccine\n\n          -  Participation in another interventional clinical trial investigating a vaccine, drug,\n             medical device, or medical procedure in the 30 days preceding the first study\n             vaccination or during the course of the study unless no intervention for the other\n             study occurred within the 30 days prior to the first study vaccination and none are\n             planned before the subject would complete safety surveillance for the present study\n\n          -  Prior vaccination with any formulation of 2013-2014 influenza vaccine\n\n          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             which may be a contraindication for intramuscular (IM) vaccination, at the discretion\n             of the Investigator\n\n          -  Thrombocytopenia, which may be a contraindication for IM vaccination, at the\n             discretion of the Investigator\n\n          -  Any condition that in the opinion of the Investigator would pose a health risk to the\n             subject if enrolled or could interfere with the evaluation of the vaccine\n\n          -  Personal history of Guillain-Barr\u00e9 syndrome\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy\n             within the preceding 6 months; or long-term systemic corticosteroid therapy\n             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n\n          -  Personal history of clinically significant developmental delay (at the discretion of\n             the Investigator), neurologic disorder, or seizure disorder\n\n          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, or\n             hepatitis C\n\n          -  Moderate or severe acute illness/infection (according to Investigator judgment) on\n             the day of vaccination or febrile illness (temperature \u2265 100.4\u00b0F]). A prospective\n             subject should not be included in the study until the condition has resolved or the\n             febrile event has subsided\n\n          -  Receipt of immune globulins, blood, or blood-derived products in the past 3 months\n\n          -  Identified as a natural or adopted child of the Investigator or an employee with\n             direct involvement in the proposed study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "8 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946425", 
            "org_study_id": "GRC51", 
            "secondary_id": "U1111-1120-1262"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study Group 1", 
                "description": "0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)", 
                "intervention_name": "Fluzone\u00ae Quadrivalent Influenza Virus Vaccine, No Preservative", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone\u00ae Quadrivalent, No Preservative"
            }, 
            {
                "arm_group_label": "Study Group 2", 
                "description": "0.5 mL, Intramuscular (2013-2014 formulation )", 
                "intervention_name": "Fluzone\u00ae Quadrivalent Influenza Virus Vaccine, No Preservative", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone\u00ae Quadrivalent, No Preservative"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Influenza", 
            "Influenza virus vaccine", 
            "Fluzone\u00ae Quadrivalent Influenza Virus Vaccine (No Preservative)"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bardstown", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40040"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84121"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Immunogenicity Among Healthy Children Receiving Fluzone\u00ae Quadrivalent Influenza Virus Vaccine (2013-2014 Formulation)", 
        "overall_official": {
            "affiliation": "Sanofi Pasteur Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Participants 6 Months to < 36 Months of Age Solicited injection site reactions: Tenderness, Redness, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability. Participants 3 Years to < 9 Years of Age: Solicited injection site reactions: Pain, Redness, and Swelling; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia. Unsolicited adverse events, including serious adverse events will also be collected for all participants.", 
            "measure": "Number of participants reporting solicited injection site and systemic events and unsolicited adverse events following vaccination with Fluzone Quadrivalent vaccine.", 
            "safety_issue": "No", 
            "time_frame": "Day 0 up to Day 28 post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946425"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated.", 
                "measure": "Geometric mean titers of antibodies to vaccine antigens following vaccination with Fluzone Quadrivalent vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 28 after final vaccination"
            }, 
            {
                "description": "Seroprotection is defined as: A titer \u2265 40 (l/dil) at pre vaccination and at Day 28 after the final vaccination. Seroconversion is defined as: Either a pre vaccination titer < 10 (1/dil) and a post vaccination titer \u2265 40 (1/dil), or a pre vaccination titer \u2265 10 (1/dil) and a \u2265 4 fold increase in post vaccination titer at Day 28 after the final vaccination.", 
                "measure": "Seroprotection and seroconversion to vaccine antigens following vaccination with Fluzone\u00ae Quadrivalent vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 28 after final vaccination"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}